Resumo

MUNOZ OSPINA, Beatriz Elena  e  OROZCO VELEZ, Jorge Luis. Clinical spectrum, evaluation and treatment of cognitive disorder and dementia associated with Parkinson's disease. Acta Neurol Colomb. [online]. 2019, vol.35, suppl.1, pp.33-46. ISSN 0120-8748.  https://doi.org/10.22379/24224022248.

The prevalence of minimal cognitive impairment in patients with PD is between 20-50 °%. The prevalence of dementia associated with the disease is estimated at around 25-30 °% with a proportional increase in relation to age and time of disease progression. The clinical profile can be heterogeneous and refers to the alteration in the different domains that a different neurobiological substrate supposes. Executive dysfunction is usually more frequent in the early stages of the disease, although there are also clinical cortical profiles. There are neuropsychiatric symptoms such as depression, anxiety and impulse control disorders that can affect cognition. The routine assessment of activities of daily living and functional performance has been related to the degree of commitment as well as to the overall cognitive performance. Patients in advanced stages and candidates for deep brain stimulation surgery require neuropsychological evaluation to monitor and identify potential risks or cognitive, behavioral and/or emotional contraindications. The conclusions of the consensus of cognition are 1. Minimal cognitive deterioration is common in patients even in early stages, 2. The clinical profile is heterogeneous, although executive dysfunction is more frequent, 3. An initial assessment allows detecting risk profiles to dementia, 4. Validated instruments should be used for this population, 5. Neuropsychiatric symptoms can affect the patient's performance and 6. The assessment of functional independence allows for exploring the impact of cognition in everyday life.

Palavras-chave : Parkison's Disease; mild cognitive impairment; dementia (MeSH).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )